Fathima Thowfeik
About Fathima Thowfeik
Fathima Thowfeik is a Quality Control Scientist at Bristol Myers Squibb in Summit, New Jersey, with a PhD in Biochemistry from the University of Cincinnati and a B.Sc. in Computational Chemistry from the University of Colombo.
Title
Fathima Thowfeik holds the position of Quality Control Scientist at Bristol Myers Squibb. She is based in Summit, New Jersey, United States. In her role, she applies her extensive background in biochemistry, computational chemistry, and biological sciences.
Education and Expertise
Fathima Thowfeik achieved her Doctor of Philosophy (PhD) in Biochemistry from the University of Cincinnati, where she studied from 2011 to 2016. Prior to this, she completed a Bachelor of Science (B.Sc.) in Computational Chemistry at the University of Colombo, studying from 2006 to 2011. Her academic journey began at Muslim Ladies College, where she studied Biology/Biological Sciences, General, from 1990 to 2004.
Industrial Experience in Cell Line Development
Fathima has notable industrial experience, particularly in cell line development. This specialty contributes significantly to her role at Bristol Myers Squibb, where precise and reliable quality control processes are essential. Her experience enables her to address complex biological challenges and contribute effectively to her team's objectives.
Skills in Technical Communication and Problem Solving
Fathima is recognized for her strong skills in technical communication and problem solving. Her ability to clearly convey complex scientific information aids in mentoring junior scientists and collaborating efficiently with colleagues. Additionally, her problem-solving skills are critical in ensuring the integrity and quality of processes within her role.
Experience with Cancer Biology and Drug Development
Fathima Thowfeik has extensive experience in studying the tumor microenvironment, immunotherapy, small molecule anti-cancer agents, drug toxicology, and cancer/cell biology. This expertise supports her contributions to developing and ensuring the effectiveness of cancer treatment options at Bristol Myers Squibb.